Recent Acquisition As part of its transition following the acquisition by pSivida Corp. in March 2018, Icon Bioscience may be seeking innovative solutions to support integration challenges and rebranding efforts.

Modest Revenue With revenues under one million dollars and a small team of 2-10 employees, the company could benefit from scalable tools and services aimed at boosting operational efficiency and growth.

Industry Focus Specializing in ophthalmic pharmaceuticals, Icon Bioscience presents opportunities for suppliers of specialized manufacturing, packaging, and research services tailored to biotech and pharma firms.

Technology Stack The company utilizes modern web technologies, indicating an openness to digital solutions that enhance product development, marketing, or e-commerce capabilities.

Market Positioning Given its size and the competitive landscape with larger players like Regeneron and Novartis, strategic partnerships or niche biotech collaborations could be key sales prospects for specialized biotech and pharmaceutical solutions.